



GAU - 1615

PATENT APPLICATION
DOCKET NO.: 00537/194002 - 087P/USPCT2/US

TECH CENTER 16002800

APR 22 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Katy Drieu et al.

Application No.: 10/018,448

Group Art Unit: 1615

Filed: March 20, 2002

Examiner: Unknown

Title: USE OF GINKGO EXTRACT

CERTIFICATE OF MAILING

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Date of Deposit: 4-17-2003

Alan F. Feeney

1st SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT AND AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

☒ under 37 CFR 1.97(b), or
(Within three months of filing national application; or date of entry of the national stage in international application; or before mailing date of first office action on the merits; whichever occurs last)

☐ under 37 CFR 1.97(c) together with either:
☐ a Statement under 37 CFR 1.97(e), as checked below, or
☐ a \$240.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:
☐ a Statement under 37 CFR 1.97(e), as checked below, and
☐ a Petition under 37 CFR 1.97(d)(2), and
☐ a \$130.00 petition fee set forth in 37 CFR 1.17(i).
(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

☐ Applicant requests that the attached IDS and cited reference(s) [] be placed in the application filewrapper.
(Filed after payment of issue fee)

☒ Some listed references were cited in the Search Report which issued in connection with the corresponding European Patent Application.

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449, with copies of the references noted thereon.
- ☐ Copies of the reference(s) noted on the enclosed form 1449 were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. [], from which the present application claims benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)).

Concise Explanation Requirement (non-English references):

- ☐ The "concise explanation" requirement for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ the enclosed English language translation.

It is requested that the information disclosed herein be made of record in this application, and that the references listed on the enclosed form PTO-1449 appear under the "References Cited" heading of any Patent which issues from this application, (MPEP 1302.12).

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.
- ☒ No fee is believed to be due for this submission. However Applicant(s) hereby authorize the Assistant Commissioner to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. Two copies of this Statement are enclosed.
- ☒ The Assistant Commissioner is hereby authorized to please charge any deficiency in fees and credit any overpayment to Deposit Account 50-0590. Two copies of this Statement are enclosed.

Respectfully submitted,

BIOMEASURE, INCORPORATED

Dated: 4-17-2003

By


Alan F. Feeney, Attorney for Applicant(s)

Registration No.: 43,609

Telephone: (508) 478-0144

Facsimile: (508) 473-3531

27 Maple Street
Milford, Massachusetts 01757

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
00537/194002APPLICATION NO.
10/018,448INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

APPLICANT
Katy Drieu et al.FILING DATE
December 13, 200GROUP
1615

U.S. PATENT DOCUMENTS

EXAM- INER INT		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	BA	5,541,183	7/30/96	Park et al.			
	BB	5,346,894	9/13/94	Korth			
	BC	5,002,965	3/26/91	Ramwell			
	BD	4,734,280	3/29/88	Braquet			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	BE	WO 95/18131	7/06/95	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	BF	Bernardini, R. et al., "The Alkyl-Ether Phospholipid Platelet-Activating Factor is a Stimulator of the Hypothalamic-Pituitary-Adrenal Axis in the Rat", Endocrinology 125(2):1067-1073 (1989).					
	BG	Blasquez, C. et al., "Effect of Platelet-Activating Factor on Hypothalamic and Hypophyseal Pro-Opiomelanocortin-Related Peptides and Hypothalamo-Pituitary-Adrenal Axis in the Rat", European Journal of Pharmacology, 177:145-153 (1990).					
	BH	Boralle, N. et al., "Ginkgo Biloba: A Review of its Chemical Composition", Ginkgolides-Chemistry, Biology, Pharmacology and Clinical Perspectives, Edited by P. Braquet, Ph.D., D.Sc., J.R. Prous Science Publishers, S.A., Les Plessis Robinson, France, 1:9-25 (1988).					
	BI	Bruel, A. et al., "Effects of Ginkgo Biloba Extract on Glucose Transport and Glycogen Synthesis of Cultured Smooth Muscle Cells from Pig Aorta", Pharmacological Res., 21(4):421-429, (1989).					
	BJ	Krieglstein, J., "Neuroprotective Properties of Ginkgo Biloba - Constituents", Z. Phytother, 15:92-96 (1994).					
	BK	Oliver, C. et al., "Effect of Ginkgo Biloba Extract on the Hypothalamo-Pituitary-Adrenal Axis and Plasma Catecholamines Levels in Stress", Eur J. Endocrinol., 130(Suppl 2): P3.072 (ABSTRACT) (1994).					
		Petkov, V.P. et al., "Effects of Standardized Extracts GK501, from Ginkgo Biloba L., G115 from Panax ginseng C.A. Meyer, and their Combination, Gincosan® (PHL-00701), on the Brain Levels of Biogenic Monamines and on the Serum Content of Prolactin, Growth Hormone and ACTH", Phytotherapy Res., 7:139-145 (1993).					
		Porsolt, R. et al., "Effects of an Extract of Ginkgo Biloba (EGB 761) on "Learned Helplessness" and Other Models of Stress in Rodents", Pharmacology Biochemistry & Behavior, 36:963-971 (1990).					

EXAMINER

DATE CONSIDERED



TECH CENTER 160012960

APR 22 2003

RECEIVED



PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
00537/194002APPLICATION NO.
10/018,448APPLICANT
Katy DrieuFILING DATE
June 12, 2001GROUP
1615

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BN	Rapin, J. et al., "Demonstration of the "Anti-Stress" Activity of an Extract of Ginkgo Biloba (EGb 761) Using a Discrimination Learning Task", Gen. Pharmac., 25(5):1009-1016 (1994).
BO	Rapin, J. et al., "Effects of Repeated Treatments With an Extract of Ginkgo Biloba (EGb 761) and Bilobalide on Glucose Uptake and Glycogen Synthesis in Rat Erythrocytes: An Ex Vivo Study", Drug Devel. Res., 31:164-169 (1994).
BP	Rodriguez De Turco, E. et al., "EGb 761 Inhibits Stress-Induced Polydipsia in Rats", Physiology & Behavior, 53:1001-1002 (1993).
BQ	Rote Liste (1994), Edited by Cantor. Aulendorf/Wurtt, ECV, Frankfurt, Germany, 94/0112:36001-36012 (1994).
BR	Vasseur, M. et al., "Effects of Repeated Treatments with an Extract of Ginkgo Biloba (EGb 761), Bilobalide and Ginkgolide B...", Gen. Pharmacology, 25(1):31-46 (1994).

RECEIVED

APR 22 2003

EXAMINER

DATE CONSIDERED

TECH CENTER 160012900